BHST: BioHarvest's Premium Fragrance Deal and Q2 Performance

BioHarvest Sciences Inc (NASDAQ:BHST) reported a 3.8% increase in Q2 revenue, with CEO Dr. Zaki Rakib shifting focus to manufacturing capacity. Revenue reached $8.8 million, up from $8.8 million year-over-year. Net loss narrowed to $3.7 million from $3.7 million, but EBITDA losses widened to $1.6 million. Cash reserves grew to $16.25 million, a significant jump from $3.7 million in the prior period.

Strategic Move with Premium Fragrance Agreement

■A deal was signed for 20 tons of high-value fragrance material with a UAE-based customer.

■The material, priced at over $10,000/kg, targets demand in Middle East, Asia, and Western luxury perfume markets.

■Production is expected to begin in the first half of 2027.

Key Takeaways for Investors

■CDMO revenue guidance tightened to $4M-$5M.

■VINIA D2C revenue now expected between $33M-$35M.

■A $1.4 million grant from the Israel Innovation Authority advanced AI and automation projects.

Markets are viewing this as a pivotal moment for BioHarvest's Botanical Synthesis technology, showcasing its potential in high-value industries. The $10,000/kg material deal suggests a strategic play to boost recurring revenue.